News – Page 462 – Endpoints News

#ESMO22: AstraZeneca takes different approach to CTLA-4 with bispecific — but toxicities remain high

3 years ago

Bristol Myers Squibb scores TYK2 OK; ARCH backs mRNA platform play; Illumina’s $8B conundrum; Sizing up Alnylam's ...

3 years ago

Bristol Myers wins a megablockbuster bet with TYK2 FDA approval — and there's a big bonus for the label

3 years ago

Manufacturers sound off on FDA drug reporting guidance, pointing to challenges and recommendations

3 years ago

Colorado to seek FDA approval by fall on Canadian drug imports

3 years ago

Merck Foundation debuts $20M health equity fund focused on cancer care

3 years ago

J&J settles gender discrimination and retaliation allegations involving former CEO and R&D head

3 years ago

$100 for a Covid-19 vaccine? That's what Moderna says may be coming

3 years ago

Pharma companies need to speak the right language to reach growing Hispanic patient populations

3 years ago

Brand name inhalers are very good at blocking competition, better even than nebulizers, study finds

3 years ago

After painful flop late last year, Allakos reveals new PhIII data and pivots to new indications

3 years ago

#ESMO22: Adaptimmune touts new PhI data for its cell therapy treatment

3 years ago

#ESMO22: At five-year mark, Lynparza kept more patients alive than Avastin but missed overall OS significance

3 years ago

Deerfield backs a Penn spinout aiming to shake up Parkinson's treatments using stem cells, brain surgery

3 years ago

#ESMO22: Data on two key checkpoint failures highlight Merck's dominance in adjuvant setting

3 years ago

#ESMO22: Here are the disastrous data that crushed hopes for a $3.6B Bristol Myers combo deal

3 years ago

'The urgency is increasing': Moderna spotlights vaccine, orphan drug programs, as it plots growth beyond Covid

3 years ago

Imara sells failed blood disorder drug to heart disease outfit Cardurion

3 years ago

Homology sails with same captains in different seats; Ex-Harpoon chief weathers the Storm at UK biotech

3 years ago

Teva fires back at GSK again over potential 'skinny' label SCOTUS case

3 years ago

Amgen's Neulasta gains another biosimilar competitor as sales slip

3 years ago

Pharma and healthcare digital ad spending slows after pandemic increase, but still headed for $20B — report

3 years ago

Manufacturing roundup: Catalent expands in Singapore; Cambrex completes first phase of $30M NC expansion

3 years ago

Merck KGaA continues expansion with $285M+ investment in 2 new projects in France and Germany

3 years ago

First page Previous page 459 460 461462463 464 465 Next page Last page